BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37850462)

  • 1. Revolutionizing antiretroviral therapy for human immunodeficiency virus/AIDS: A computational approach using molecular docking, virtual screening, and 3D pharmacophore building to address therapeutic failure and propose highly effective candidates.
    Annan A; Raiss N; Elmir EH; Filali-Maltouf A; Medraoui L; Oumzil H
    Int J Immunopathol Pharmacol; 2023; 37():3946320231207514. PubMed ID: 37850462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proposal of pharmacophore model for HIV reverse transcriptase inhibitors: Combined mutational effect analysis, molecular dynamics, molecular docking and pharmacophore modeling study.
    Annan A; Raiss N; Lemrabet S; Elomari N; Elmir EH; Filali-Maltouf A; Medraoui L; Oumzil H
    Int J Immunopathol Pharmacol; 2024; 38():3946320241231465. PubMed ID: 38296818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Combined Approach of Pharmacophore Modeling, QSAR Study, Molecular Docking and In silico ADME/Tox Prediction of 4-Arylthio & 4-Aryloxy-3- Iodopyridine-2(1H)-one Analogs to Identify Potential Reverse Transcriptase Inhibitor: Anti-HIV Agents.
    Panigrahi D; Mishra A; Sahu SK; Azam MA; Vyshaag CM
    Med Chem; 2022; 18(1):51-87. PubMed ID: 33319692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current insights and molecular docking studies of HIV-1 reverse transcriptase inhibitors.
    Singh AK; Kumar A; Arora S; Kumar R; Verma A; Khalilullah H; Jaremko M; Emwas AH; Kumar P
    Chem Biol Drug Des; 2024 Jan; 103(1):e14372. PubMed ID: 37817296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Per-residue energy decomposition pharmacophore model to enhance virtual screening in drug discovery: a study for identification of reverse transcriptase inhibitors as potential anti-HIV agents.
    Cele FN; Ramesh M; Soliman ME
    Drug Des Devel Ther; 2016; 10():1365-77. PubMed ID: 27114700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of anti-HIV-1 drugs.
    Lu XF; Chen ZW
    Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docking-based 3D-QSAR and pharmacophore studies on diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Liu G; Wan Y; Wang W; Fang S; Gu S; Ju X
    Mol Divers; 2019 Feb; 23(1):107-121. PubMed ID: 30051344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
    Tabassum T; Azeem SM; Muwonge AN; Frey KM
    Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors.
    Liu G; Wang W; Wan Y; Ju X; Gu S
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutting into the Substrate Dominance: Pharmacophore and Structure-Based Approaches toward Inhibiting Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H.
    Wang L; Sarafianos SG; Wang Z
    Acc Chem Res; 2020 Jan; 53(1):218-230. PubMed ID: 31880912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Non-Nucleoside Reverse Transcriptase Inhibitor against Human Immunodeficiency Virus-1.
    Kim MJ; Yu KL; Han R; Lee Y; Oh K; You JC
    ACS Infect Dis; 2023 Aug; 9(8):1582-1592. PubMed ID: 37415514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    De Clercq E
    Farmaco; 1999; 54(1-2):26-45. PubMed ID: 10321027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
    De Clercq E
    Adv Pharmacol; 2013; 67():317-58. PubMed ID: 23886005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors.
    Barreca ML; De Luca L; Iraci N; Rao A; Ferro S; Maga G; Chimirri A
    J Chem Inf Model; 2007; 47(2):557-62. PubMed ID: 17274611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors.
    Santos LH; Ferreira RS; Caffarena ER
    Mem Inst Oswaldo Cruz; 2015 Nov; 110(7):847-64. PubMed ID: 26560977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hit identification and drug repositioning of potential non-nucleoside reverse transcriptase inhibitors by structure-based approach using computational tools (part II).
    Cutinho PF; Shankar RC; Anand A; Roy J; Mehta CH; Nayak UY; Murahari M
    J Biomol Struct Dyn; 2020 Aug; 38(13):3772-3789. PubMed ID: 31526232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme.
    Fabian L; Taverna Porro M; Gómez N; Salvatori M; Turk G; Estrin D; Moglioni A
    Eur J Med Chem; 2020 Feb; 188():111987. PubMed ID: 31893549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress of bis(heteroaryl)piperazines (BHAPs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against human immunodeficiency virus type 1 (HIV-1).
    Xu H
    Mini Rev Med Chem; 2010 Jan; 10(1):62-72. PubMed ID: 20380641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of metronidazole derivatives and flavonoids as potential non-nucleoside reverse transcriptase inhibitors using combined ligand- and structure-based approaches.
    Cutinho PF; Roy J; Anand A; Cheluvaraj R; Murahari M; Chimatapu HSV
    J Biomol Struct Dyn; 2020 Apr; 38(6):1626-1648. PubMed ID: 31046644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of 3-((1-(Benzyl(2-hydroxy-2-phenylethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamoyl)pyrazine-2-carboxylic Acid as a Potential Inhibitor of Non-Nucleosidase Reverse Transcriptase Inhibitors through InSilico Ligand- and Structure-Based Approaches.
    Mathpal D; Almeleebia TM; Alshahrani KM; Alshahrani MY; Ahmad I; Asiri M; Kamal M; Jawaid T; Srivastava SP; Saeed M; Balaramnavar VM
    Molecules; 2021 Aug; 26(17):. PubMed ID: 34500699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.